TC方案化疗联合同期放疗治疗中晚期鼻咽癌临床观察.pdf

现代肿瘤医学2011年01月第19卷第01期
TC方案化疗联合同期放疗治疗中晚期鼻咽癌临床观察
邹雨荷,田鲜艳,何景扬,王羽,张钦华
A clinical research of docetaxel plus carboplatin with concurrent radiotherapy in the treat-
ment of locally advanced nasopharyngeal carcinoma
ZOU Yu-he, TIAN Xian-yan, HE Jing yang, WANG Yu, ZHANG Qin-hua
Department of oncology, the Central Hospitol of Jiangmen city, guangdong 529070, China
Astacobecte: T evaluae the effect and toxicity of docetaxel plus carboplatin with concurrent radiother-
py in the treatment of locally advanced nasopharyngeal carcinoma. Methods: Total of 86 cases with locally advanced
nasopharyngeal carcinoma(stage Ill and Iva )were randomized into 2 groups. Group TC(n=42 ) received radiother
py with docetaxel plus carboplatin(docetaxel 135mg/m,, carboplatin AUC=6 d1) Group PF(n=44)received
cisplatin 20mg/m iv d-s, 5-FU 500 mg/miv d, -s at the 1st and 4th week and received radiotherapy. Results
The rates of 1, 3-year survival were 100%(42/42), 73.8%(31/42)in TC group while in PF group were 97.7%
(43/44 )and 79.5%(35/44), there were no sig fian differences(P>0.05). For TC group, the oral mucositis
and gastrointestinal reaction were less the PF group(P<0.05) No significant differences in the locoregional contol
rate and distant contol rate and myelosuppression were found between two groups(P>0.05). Conclusion: Radiother
apy with concurrent docetaxel plus carboplatin chemotherapy for locally advanced nasopharyngeal carcinoma is tolera.
ble, and the efficacy is satisfied
Key words) nasopharyngeal carcinoma; concurrent radiochemotherapy; carboplatin; docetaxel
Modern Oncology2011,19(01):0029-0031
摘要】目的:观察紫杉醇+卡铂同期放化疗治疗中晚期鼻咽癌的疗效及不良反应。方法:86例确诊为中晚
期鼻咽瘺患者随机分为治疗组TC同期放化疗组42例和对照组PF同期放化疗组44例,TC组在放射治疗的
第14周给予2个周期紫杉醇ャ卡铂方案化疗(紫杉醇135mg/m2dl,卡铂AUC=6dl;PF组在放射治疗的第
1、4周给予2个周期5-FU+顺铂方案化疗(顺铂20mg/m2iyd,s,5-FU500mg/m2)。结果:TC组1、3年
生存率分别为100%(42/42)、73.8%(36/50),PF组91.0%(43/44)、78.0%(35/44)(P>0.05);TC组口腔
黏膜损伤、消化道反应明显低于PF组(P<0.05)。两组局部控制率、远处转移率及骨髓功能抑制无统计学
差异(P>0.05)。结论:紫杉醇+卡铂同步放化疗治疗局部晚期吳咽癌耐受性好,疗效满意。
【关键词】鼻咽癌;同步放化疗;紫杉醇;卡铂
【中图分类号)R739.63
【文献标识码】A
DOI:10.3969/j.issn.1672-4992.201.01.10
文章编号】1672-4992-(2011)01-0029-03
鼻咽癌在我国南方为较常见恶性肿瘤,就诊时70%已是1.1临床资料
局部晚期,治疗失败原因为局部未控及远处转移,在中晚期
收集2004.1-2006.10NPC患者86例(男63例,女23
鼻咽癌治疗中,同步放化疗已达到一致公认,与单纯放疗比例),年龄21-71岁。人选标准:鼻咽活检确诊为分化癌、
校可提高无病生存期及总生存期-?。近些年研究中除传未分化癌;初治患者,未接受其他抗肿瘤治疗;TN。-2M0
统的顺铂+5FU化疗方案,其他方案为数不多,而传统的化T3N2MⅢ期,TN。M0、To:NY3MIN。期; Karnofsky评分≥
疗方案因黏膜及胃肠道反应大,化疗维持时间长,思者耐受70分:心、肝、肾功能正常;白细胞≥4.0×10°/L。全组病例
性依从性差。本研究探讨紫杉醇联合卡铂方案与传统铂随机分配进入P同步放化疗组42例(男33例,女9例),
+5-FU方案放疗同期化疗比较,评估其方案可行性机及临床疗PF同步放化疗组44例(男30例,女14例),Ⅲ期36例,Ⅳ,
效
期52例。两组间年龄、性别比例、临床分期差异均无显著
1资料与方法
性。(见表1
1.2治疗方法
【收稿日期】2010-05-19
【修回日期)】2010-1-10
1,2,1放疗方法
【作者单位】广东省江门市中心医院肿瘤科,广东江『门529030
两组放射治疗方法一致,所有病例均经同一专家组讨
【作者简介】邹雨荷(1968-)女,广东江门人,副主任医师,主要从论制定放疗计划,采用常规CT- simulation(CT-sim)设计
事恶性肿瘤放化疗及生物治疗。
的标准治疗,热塑面罩泡淋枕体位固定。使用西门子直线